Inovio (INO) announced that the FDA has notified the company that it agrees with its rolling submission timeline for the BLA for INO-3107 as a treatment for adults with Recurrent Respiratory Papillomatosis. Inovio anticipates completing its submission to the FDA in the coming months and requesting priority review, with the goal of file acceptance by the FDA by the end of 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INO:
- Inovio Pharmaceuticals: Hold Rating Amid Financial Challenges and Competitive Pressures
- Inovio Pharmaceuticals Reports Q2 2025 Financial Progress
- Inovio reports Q2 EPS (61c), consensus (62c)
- Options Volatility and Implied Earnings Moves Today, August 12, 2025
- Inovio announces peer-reviewed data from INO-3107 study